While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

"Ozempic is very easy to get nowadays, and people all over are getting their hands on it. But don't do it. I messed up.

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

The deal comes as Novo Nordisk moves to become the leader ... The Danish maker of Ozempic has dominated the space with its Wegovy, but is facing competition from Eli Lilly's Zepbound (tirzepatide).

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...